Biocon Biologics | Advancing Biosimilars for a Healthier and Affordable Future

BIG PICTURE

Biosimilars save
the US healthcare
system an estimated
$5.4 billion each year*.

Biocon Biologics is a proud leader in the advancement of biosimilars. As we continue to drive innovation and invest in the future, our mission is singularly focused on the development, manufacturing, distribution, and commercialization of the highest quality biosimilars in the world.

Biocon Biologics

A fully integrated global biosimilars company, all in on biosimilars.

A unique biosimilars portfolio spanning insulins, recombinant proteins, and monoclonal antibodies
Cutting-edge science and research capabilities
Experience built from successful global partnership with Mylan/Viatris
Global-scale manufacturing with high standards of quality and compliance

20+

biosimilars approved or in development

biosimilars launched across global markets

100+

countries where biosimilars are available

5.5 M

served globally by Biocon Biologics' biosimilars

* Estimates ofreductions in direct spending on biologic drugs from 2014 through 2024.
Reference: Mulcahy AW, Hlavka JP, Case SR. Biosimilar cost savings in the United States: initial experience and future potential. Rand Health Q. 2018;7(4):3.

LEGACY OF SUCCESS

A long-standing presence in the biosimilars industry

Biocon Biologics has emerged as a leader in biosimilars in the US and worldwide, providing innovative and more affordable ways to treat diabetes, cancer, and autoimmune diseases. As a result of its successful global partnership with Viatris, Biocon Biologics has broadened its biosimilars capability from lab to market, commercializing the products it has been making for years.

Founded to
improve access to
quality bioenzymes

Evolves into
bio-pharmaceuticals

First and only
company to
commercialize a
Pichia pastoris
derived rh-insulin
rh=recombinant human

Partners with
US-based Mylan to
co-develop
biosimilar
antibodies portfolio for global markets

Launches world's
first trastuzumab
biosimilar

Solidifies foothold
in US and global
biosimilars space

Continues
partnership with
Viatris after
Mylan/Upjohn
merger

Biocon Biologics
acquires Viatris'
global biosimilars
business to become
a fully integrated
biosimilars
company in the US

PORTFOLIO

Path-breaking
offerings with a focus
on the future.

With a unique portfolio of monoclonal antibodies and insulins, Biocon Biologics is fully committed to the long-term sustainability of global biosimilars access, investing more than $1 billion in R&D and global-scale manufacturing over the last 2 decades.

FULPHILA®
(pegfilgrastim-jmdb)
injection*
FIRST to receive
US approval - 2018
(5+ global markets)

OGIVRI®
(trastuzumab-dkst)
injection†‡
FIRST to receive
US approval - 2017
(5+ global markets) †Please see accompanying full US Prescribing Information, including BOXED WARNING.

Bevacizumab‡
Approved in EU 2021
(3+ global markets)
Filed for US approval

Denosumab‡
In global clinical trials

Pertuzumab‡
In global clinical trials

HULIO®
(adalimumab-fkjp)
injection†‡§¶
US approval 2020
Approved in EU 2018
(3+ global markets) †Please see accompanying full US Prescribing Information, including BOXED WARNING.

Etanercept§
Approved in EU 2020
(EU market)

Ustekinumab‡
Filed for US approval